For You
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Edition: ENGLISH
DEUTSCH
ESPAÑOL
FRANÇAIS
PORTUGUÊS
Sign Up It's Free!
Edition: ENGLISH DEUTSCH ESPAÑOL FRANÇAIS PORTUGUÊS

No Results

    For You News & Perspective Drugs & Diseases CME & Education Academy Video
    Drugs & Diseases > Medscape > Fast Five Quizzes

    Fast Five Quiz: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

    Karl J. D'Silva, MD

    Disclosures

    June 23, 2020

    Refractory CLL is defined as failure to achieve a response or having disease progression within 6 months of the last treatment.

    Learn more about CLL guidelines.

    Comments

    3090D553-9492-4563-8681-AD288FA52ACE
    Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
    Return to Article
    Post as:

    processing....

    Feedback
    Help us make reference on Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this article more useful to clinicians.
    Pleasedo not use this form to submit personal or patient medical information or to report adverse drug events. You are encouraged to report adverse drug event information to the FDA.

    Find Us On

    Group 2 34A8E98B-62ED-4216-98D6-E986304F4C2E

    About

    About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center

    Membership

    Become a Member Manage My Account About You Professional Information Newsletters & Alerts

    Apps

    Medscape CME & Education

    WebMD Network

    Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate

    Editions

    English Deutsch Español Français Português
    All material on this website is protected by copyright, Copyright © 1994-2021 by WebMD LLC. This website also contains material copyrighted by 3rd parties.